Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: In 2017, an estimated 14 million cases of Plasmodium vivax malaria were reported from Asia, Central and South America, and the Horn of Africa. The clinical burden of vivax malaria is largely driven by its ability to form dormant liver stages (hypnozoites) that can reactivate to cause recurrent episodes of malaria. Elimination of both the blood and liver stages of the parasites (“radical cure”) is required to achieve a sustained clinical response and prevent ongoing transmission of the parasite. Novel treatment options and point-of-care diagnostics are now available to ensure that radical cure can be administered safely and effectively. We quantified the global economic cost of vivax malaria and estimated the potential cost benefit of a policy of radical cure after testing patients for glucose-6-phosphate dehydrogenase (G6PD) deficiency. Methods and findings: Estimates of the healthcare provider and household costs due to vivax malaria were collated and combined with national case estimates for 44 endemic countries in 2017. These provider and household costs were compared with those that would be incurred under 2 scenarios for radical cure following G6PD screening: (1) complete adherence following daily supervised primaquine therapy and (2) unsupervised treatment with an assumed 40% effectiveness. A probabilistic sensitivity analysis generated credible intervals (CrIs) for the estimates. Globally, the annual cost of vivax malaria was US$359 million (95% CrI: US$222 to 563 million), attributable to 14.2 million cases of vivax malaria in 2017. From a societal perspective, adopting a policy of G6PD deficiency screening and supervision of primaquine to all eligible patients would prevent 6.1 million cases and reduce the global cost of vivax malaria to US$266 million (95% CrI: US$161 to 415 million), although healthcare provider costs would increase by US$39 million. If perfect adherence could be achieved with a single visit, then the global cost would fall further to US$225 million, equivalent to $135 million in cost savings from the baseline global costs. A policy of unsupervised primaquine reduced the cost to US$342 million (95% CrI: US$209 to 532 million) while preventing 2.1 million cases. Limitations of the study include partial availability of country-level cost data and parameter uncertainty for the proportion of patients prescribed primaquine, patient adherence to a full course of primaquine, and effectiveness of primaquine when unsupervised. Conclusions: Our modelling study highlights a substantial global economic burden of vivax malaria that could be reduced through investment in safe and effective radical cure achieved by routine screening for G6PD deficiency and supervision of treatment. Novel, low-cost interventions for improving adherence to primaquine to ensure effective radical cure and widespread access to screening for G6PD deficiency will be critical to achieving the timely global elimination of P . vivax .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The availability of novel point of care diagnostics for G6PD deficiency have potential to impact policy by identifying patients who can safely tolerate tafenoquine and higher dose primaquine regimens, however this comes at an increased cost to health systems [32].”
From Plasmodium vivax relapse reservoirs in Ethiopia: microhaplotype sequencing informs recurrent infection origins (2026) · cites this paper as [32]
In the citing paper
“The burden of relapse in Ethiopia likely carries a substantial, clinical cost at both the individual and community level [32].”
From Plasmodium vivax relapse reservoirs in Ethiopia: microhaplotype sequencing informs recurrent infection origins (2026) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015
Bhatt, S., Weiss, D. J., Cameron, E., Bisanzio, D., Mappin, B., Dalrymple, U., Battle, K. E., Moyes, C. L., Henry, A., Eckhoff, P. A., et al. (2015) · Nature · doi:10.1038/nature15535 · Cited by 3,225 · cited 1×
“Early diagnosis, highly effective antimalarial treatment, and intensive vector control measures have led to a major reduction in the global burden of Plasmodium falciparum [1].”
BackgroundSelf-citationBattle, K. E., Lucas, T. C. D., Nguyen, M., Howes, R. E., Nandi, A. K., Twohig, K. A., Pfeffer, D. A., Cameron, E., Rao, P. C., Casey, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31096-7 · Cited by 409 · cited 3×
“2 million cases across the 44 endemic countries included in this analysis (S1 Table) [2].”
Self-citationEvidence and Implications of Mortality Associated with Acute Plasmodium vivax Malaria
Baird, J. K. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-12 · Cited by 398 · cited 1×
“vivax forms dormant liver stages (hypnozoites) that reactivate periodically, causing recurrent episodes of malaria (relapses) associated with a cumulative risk of anaemia in addition to direct and indirect attributable mortality [4,5] and ongoing transmission of the parasite [6].”
Standardizing estimates of the Plasmodium falciparum parasite rate
Smith, D. L., Guerra, C. A., Snow, R. W., & Hay, S. I. (2007) · Malaria Journal · doi:10.1186/1475-2875-6-131 · Cited by 207 · cited 1×
“The age-specific case estimates were obtained from a model developed for falciparum malaria [23,24].”
MethodBruxvoort, K., Goodman, C., Kachur, S. P., & Schellenberg, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084555 · Cited by 135 · cited 1×
“Limited information is available on adherence to and effectiveness of a 14-day primaquine regimen [11,38].”
Moore, K. A., Simpson, J. A., Wiladphaingern, J., Min, A. M., Pimanpanarak, M., Paw, M. K., Raksuansak, J., Pukrittayakamee, S., Fowkes, F. J. I., White, N. J., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0877-6 · Cited by 111
Self-citation
Research works printed but not linked: 41
- RN Price, 2020, Plasmodium vivax in the Era of the Shrinking P. falciparum Map, Trends Parasitol, 36, 560, 10.1016/j.pt.2020.03.009 · DOI · Paper page
- S Dini, 2020, The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study., BMC Med., 18, 28, 10.1186/s12916-020-1497-0 · DOI · Paper page
- NM Douglas, 2013, Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax, J Infect Dis, 208, 801, 10.1093/infdis/jit261 · DOI
- NM Douglas, 2014, Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia, BMC Med, 12, 217, 10.1186/s12916-014-0217-z · DOI
- JR Poespoprodjo, 2009, Vivax Malaria: A Major Cause of Morbidity in Early Infancy, Clin Infect Dis, 48, 1704, 10.1086/599041 · DOI · Paper page
- World Health Organisation, 2015, Guidelines for the Treatment of Malaria
- NM Douglas, 2017, Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study, PLoS Med, 14, e1002379, 10.1371/journal.pmed.1002379 · DOI · Paper page
- T Leslie, 2004, Compliance with 14-day primaquine therapy for radical cure of vivax malaria—a randomized placebo-controlled trial comparing unsupervised with supervised treatment, Trans R Soc Trop Med Hyg, 98, 168, 10.1016/S0035-9203(03)00041-5 · DOI · Paper page
- CS Chu, 2018, Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria, Clin Infect Dis
- WRJ Taylor, 2019, Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial, Lancet, 394, 929, 10.1016/S0140-6736(19)31285-1 · DOI · Paper page
- MVG Lacerda, 2019, Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria, N Engl J Med, 380, 215, 10.1056/NEJMoa1710775 · DOI · Paper page
- EA Ashley, 2014, Primaquine: the risks and the benefits, Malar J, 13, 418, 10.1186/1475-2875-13-418 · DOI · Paper page
- RE Howes, 2012, G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map, PLoS Med., 9, e1001339, 10.1371/journal.pmed.1001339 · DOI · Paper page
- K Thriemer, 2017, Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group, Malar J., 16, 141, 10.1186/s12936-017-1784-1 · DOI · Paper page
- A Devine, 2019, Provider and household costs of Plasmodium vivax malaria episodes: a multicountry comparative analysis of primary trial data, Bull World Health Organ, 97, 828, 10.2471/BLT.18.226688 · DOI
- B Ley, 2019, Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis, PLoS Med, 16, e1002992, 10.1371/journal.pmed.1002992 · DOI · Paper page
- PW Gething, 2012, A Long Neglected World Malaria Map: Plasmodium vivax Endemicity in 2010, PLoS Negl Trop Dis, 6, e1814, 10.1371/journal.pntd.0001814 · DOI · Paper page
- JK Baird, 2018, Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms, Malar J, 17, 42, 10.1186/s12936-018-2190-z · DOI
- Management Sciences for Health. International Medical Products Price Guide, 2015 Edition. Arlington, VA: Management Sciences for Health; 2017 [cited 2017 October 26]. Available from: http://mshpriceguide.org/en/home/.
- BA Rahimi, 2014, Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900., Malar J, 13, 481, 10.1186/1475-2875-13-481 · DOI · Paper page
- C Botto-Menezes, 2016, Costs Associated with Malaria in Pregnancy in the Brazilian Amazon, a Low Endemic Area Where Plasmodium vivax Predominates, PLoS Negl Trop Dis, 10, e0004494, 10.1371/journal.pntd.0004494 · DOI
- E Kenangalem, 2019, Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: A longitudinal surveillance study, PLoS Med., 16, e1002815, 10.1371/journal.pmed.1002815 · DOI
- HM Peixoto, 2016, Cost-effectiveness analysis of rapid diagnostic tests for G6PD deficiency in patients with Plasmodium vivax malaria in the Brazilian Amazon, Malar J, 15, 82, 10.1186/s12936-016-1140-x · doi:10.1186/s12936-016-1140-x
- MR de Oliveira, 2012, Cost-effectiveness of diagnostic for malaria in Extra-Amazon Region, Brazil, Malar J, 11, 390, 10.1186/1475-2875-11-390 · DOI
- R Milligan, 2020, Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax, Cochrane Database Syst Rev, 8, Cd012656
- RJ Commons, 2020, Estimating the Proportion of Plasmodium vivax Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis, Am J Trop Med Hyg
- Q Bassat, 2016, Key Knowledge Gaps for Plasmodium vivax Control and Elimination, Am J Trop Med Hyg
- JA Mulligan, 2006, The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania, Trop Med Int Health, 11, 452, 10.1111/j.1365-3156.2006.01590.x · DOI
- JD Njau, 2008, The costs of introducing artemisinin-based combination therapy: evidence from district-wide implementation in rural Tanzania, Malar J, 7, 4, 10.1186/1475-2875-7-4 · doi:10.1186/1475-2875-7-4
- AR Taylor, Resolving the cause of recurrent Plasmodium vivax malaria probabilistically, Nat Commun, 10, 5595, 10.1038/s41467-019-13412-x · DOI · Paper page
- AI Adekunle, 2015, Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivo, PLoS Negl Trop Dis, 9, e0003595, 10.1371/journal.pntd.0003595 · DOI · Paper page
- KP Grietens, 2010, Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon, Am J Trop Med Hyg, 82, 1017, 10.4269/ajtmh.2010.09-0521 · DOI
- K Thriemer, 2018, Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group, Malar J, 17, 241, 10.1186/s12936-018-2380-8 · DOI · Paper page
- MT White, 2018, Mathematical modelling of the impact of expanding levels of malaria control interventions on Plasmodium vivax, Nat Commun, 9, 3300, 10.1038/s41467-018-05860-8 · DOI
- NM Douglas, 2012, Chemotherapeutic strategies for reducing transmission of Plasmodium vivax malaria, Adv Parasitol, 80, 271, 10.1016/B978-0-12-397900-1.00005-0 · DOI
- S Vitor-Silva, 2009, Malaria is associated with poor school performance in an endemic area of the Brazilian Amazon., Malar J., 8, 230, 10.1186/1475-2875-8-230 · DOI
- AM Lucas, 2010, Malaria Eradication and Educational Attainment: Evidence from Paraguay and Sri Lanka, Am Econ J Appl Econ, 2, 46, 10.1257/app.2.2.46 · DOI · Paper page
- AM Lucas, 2013, The Impact of Malaria Eradication on Fertility, Econ Dev Cult Change, 61, 607, 10.1086/669261 · DOI
- H. Bleakley, 2010, Malaria Eradication in the Americas: A Retrospective Analysis of Childhood Exposure, Am Econ J Appl Econ, 2, 1, 10.1257/app.2.2.1 · DOI · Paper page
- KE Battle, 2015, Defining the relationship between Plasmodium vivax parasite rate and clinical disease, Malar J, 14, 191, 10.1186/s12936-015-0706-3 · DOI
- S Pal, 2019, Evaluation of a Novel Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency: Bringing Quantitative Testing for Glucose-6-Phosphate Dehydrogenase Deficiency Closer to the Patient, Am J Trop Med Hyg, 100, 213, 10.4269/ajtmh.18-0612 · DOI · Paper page
Cited by
Osborne, A. A., Ruybal-Pesantez, S., Rai, A., Trimarsanto, H., Hoon, K. S., Piera, K., Kleinecke, M., Rumaseb, A., Sutanto, E., Thriemer, K., et al. (2026) · doi:10.64898/2026.11.12.765293
Self-citation
Metadata
- Authors
- Devine, A., Battle, K. E., Meagher, N., Howes, R. E., Dini, S., Gething, P. W., Simpson, J. A., Price, R. N., & Lubell, Y.
- ORCID
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-06-01
- Volume
- 18
- Issue
- 6
- Pages
- e1003614
- ISSN
- 1549-1676
- Cited by
- 33
- References
- 6
- Language
- en
- Funders
- Bill and Melinda Gates Foundation (INV-007122, INV-009390)
- National Health and Medical Research Council (1134989, 1104975)
- Wellcome Trust (200909)
- Channel 7 Telethon Trust
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.